BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhou J, Shen Q, Lin H, Hu L, Li G, Zhang X. Decitabine shows potent anti-myeloma activity by depleting monocytic myeloid-derived suppressor cells in the myeloma microenvironment. J Cancer Res Clin Oncol 2019;145:329-36. [PMID: 30426212 DOI: 10.1007/s00432-018-2790-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Yu S, Ren X, Li L. Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin. Exp Hematol Oncol 2022;11:43. [PMID: 35854339 DOI: 10.1186/s40164-022-00296-9] [Reference Citation Analysis]
2 Siemińska I, Baran J. Myeloid-Derived Suppressor Cells as Key Players and Promising Therapy Targets in Prostate Cancer. Front Oncol 2022;12:862416. [DOI: 10.3389/fonc.2022.862416] [Reference Citation Analysis]
3 Logie E, Van Puyvelde B, Cuypers B, Schepers A, Berghmans H, Verdonck J, Laukens K, Godderis L, Dhaenens M, Deforce D, Vanden Berghe W. Ferroptosis Induction in Multiple Myeloma Cells Triggers DNA Methylation and Histone Modification Changes Associated with Cellular Senescence. Int J Mol Sci 2021;22:12234. [PMID: 34830117 DOI: 10.3390/ijms222212234] [Reference Citation Analysis]
4 Zhao G, Wang Q, Li S, Wang X. Resistance to Hypomethylating Agents in Myelodysplastic Syndrome and Acute Myeloid Leukemia From Clinical Data and Molecular Mechanism. Front Oncol 2021;11:706030. [PMID: 34650913 DOI: 10.3389/fonc.2021.706030] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Zhaoyun L, Rong F. Predictive Role of Immune Profiling for Survival of Multiple Myeloma Patients. Front Immunol 2021;12:663748. [PMID: 34290698 DOI: 10.3389/fimmu.2021.663748] [Reference Citation Analysis]
6 Olivares-Hernández A, Figuero-Pérez L, Terán-Brage E, López-Gutiérrez Á, Velasco ÁT, Sarmiento RG, Cruz-Hernández JJ, Miramontes-González JP. Resistance to Immune Checkpoint Inhibitors Secondary to Myeloid-Derived Suppressor Cells: A New Therapeutic Targeting of Haematological Malignancies. J Clin Med 2021;10:1919. [PMID: 33925214 DOI: 10.3390/jcm10091919] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Maes K, Mondino A, Lasarte JJ, Agirre X, Vanderkerken K, Prosper F, Breckpot K. Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential. Front Immunol 2021;12:652160. [PMID: 33859645 DOI: 10.3389/fimmu.2021.652160] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
8 Wong KK, Hassan R, Yaacob NS. Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Front Oncol 2021;11:624742. [PMID: 33718188 DOI: 10.3389/fonc.2021.624742] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 García-Ortiz A, Rodríguez-García Y, Encinas J, Maroto-Martín E, Castellano E, Teixidó J, Martínez-López J. The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression. Cancers (Basel) 2021;13:E217. [PMID: 33435306 DOI: 10.3390/cancers13020217] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
10 Gunes EG, Rosen ST, Querfeld C. The role of myeloid-derived suppressor cells in hematologic malignancies. Curr Opin Oncol 2020;32:518-26. [PMID: 32675593 DOI: 10.1097/CCO.0000000000000662] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
11 Matsushita M, Saito S, Yokoe S, Ichikawa D, Hattori Y. Characteristics of a Novel Target Antigen Against Myeloma Cells for Immunotherapy. Vaccines (Basel) 2020;8:E579. [PMID: 33023190 DOI: 10.3390/vaccines8040579] [Reference Citation Analysis]
12 Erin N, Grahovac J, Brozovic A, Efferth T. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance. Drug Resist Updat 2020;53:100715. [PMID: 32679188 DOI: 10.1016/j.drup.2020.100715] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 16.5] [Reference Citation Analysis]
13 Li N, Liu L, Xiang P, Liang L, Wang J, Wang Y, Luo S, Song Y, Fang B. Addition of low‐dose decitabine to bortezomib and dexamethasone as second‐line therapy in multiple myeloma. Br J Haematol 2020;189. [DOI: 10.1111/bjh.16686] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
14 Colligan SH, Tzetzo SL, Abrams SI. Myeloid-driven mechanisms as barriers to antitumor CD8+ T cell activity. Mol Immunol 2020;118:165-73. [PMID: 31884388 DOI: 10.1016/j.molimm.2019.12.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
15 Palumbo GA, Parrinello NL, Giallongo C, D'Amico E, Zanghì A, Puglisi F, Conticello C, Chiarenza A, Tibullo D, Raimondo FD, Romano A. Monocytic Myeloid Derived Suppressor Cells in Hematological Malignancies. Int J Mol Sci 2019;20:E5459. [PMID: 31683978 DOI: 10.3390/ijms20215459] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]